Compare Stocks

Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities.

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ARWR Arrowhead Pharmaceuticals	$16.76 -11.1%	$16.34	$9.57 ▼ $29.86	$2.60B	0.93	1.58 million shs	3.01 million shs
LABD Direxion Daily S&P Biotech Bear 3x Shares	$6.52 +6.2%	$7.59	$4.78 ▼ $16.05	$79.97M	-2.4	16.43 million shs	25.54 million shs
LABU Direxion Daily S&P Biotech Bull 3x Shares	$62.76 -6.5%	$57.24	$32.55 ▼ $152.60	$654.21M	3	1.46 million shs	3.17 million shs
MDGL Madrigal Pharmaceuticals	$334.13 -4.2%	$291.89	$200.63 ▼ $377.46	$7.74B	-1.05	361,550 shs	326,009 shs

Reduce the Risk

Market downturns give many investors pause, and for good reason. Wondering how to offset this risk? Enter your email address to learn more about using beta to protect your portfolio.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ARWR Arrowhead Pharmaceuticals	-11.09%	-8.47%	+7.30%	+49.11%	-40.19%
LABD Direxion Daily S&P Biotech Bear 3x Shares	+6.19%	+2.03%	-13.87%	-36.82%	+11.45%
LABU Direxion Daily S&P Biotech Bull 3x Shares	-6.52%	-3.51%	+10.63%	+33.53%	-54.95%
MDGL Madrigal Pharmaceuticals	-4.19%	+5.92%	+18.18%	+10.76%	+24.03%

Compare MarketRank™

Company	Overall Score	Analyst's Opinion	Short Interest Score	Dividend Strength	ESG Score	News and Social Media Sentiment	Company Ownership	Earnings & Valuation
ARWR Arrowhead Pharmaceuticals	3.8394 of 5 stars	3.4	2.0	0.0	3.4	3.6	1.7	0.0
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	4.3465 of 5 stars	3.4	1.0	0.0	4.6	2.5	4.2	0.6

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ARWR Arrowhead Pharmaceuticals	2.75	Moderate Buy	$43.71	160.83% Upside
LABD Direxion Daily S&P Biotech Bear 3x Shares	0.00	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	2.75	Moderate Buy	$62.76	N/A
MDGL Madrigal Pharmaceuticals	2.89	Moderate Buy	$420.63	25.89% Upside

Current Analyst Ratings Breakdown

Latest LABU, MDGL, ARWR, and LABD Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
5/20/2025	ARWR Arrowhead Pharmaceuticals	HC Wainwright Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$80.00 ➝ $80.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Citigroup Subscribe to MarketBeat All Access for the recommendation accuracy rating	Lower Price Target	Neutral ➝ Neutral	$21.00 ➝ $17.00
5/13/2025	ARWR Arrowhead Pharmaceuticals	Chardan Capital Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$60.00 ➝ $60.00
5/2/2025	MDGL Madrigal Pharmaceuticals	UBS Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$441.00 ➝ $458.00
5/2/2025	MDGL Madrigal Pharmaceuticals	B. Riley Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Buy ➝ Buy	$422.00 ➝ $460.00
5/2/2025	MDGL Madrigal Pharmaceuticals	Canaccord Genuity Group Subscribe to MarketBeat All Access for the recommendation accuracy rating	Boost Price Target	Buy ➝ Buy	$394.00 ➝ $420.00
4/24/2025	MDGL Madrigal Pharmaceuticals	JMP Securities Subscribe to MarketBeat All Access for the recommendation accuracy rating	Reiterated Rating	Market Outperform ➝ Market Outperform	$443.00 ➝ $443.00

(Data available from 7/19/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ARWR Arrowhead Pharmaceuticals	$3.55M	651.99	N/A	N/A	$1.54 per share	10.88
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A	N/A	N/A	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	$317.38M	23.37	N/A	N/A	$34.59 per share	9.66

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ARWR Arrowhead Pharmaceuticals	-$599.49M	-$1.40	N/A	N/A	22.17	N/A	-45.33%	-12.49%	8/6/2025 (Estimated)
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A	N/A	0.00	∞	N/A	N/A	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	-$465.89M	-$18.05	N/A	N/A	N/A	-123.38%	-50.54%	-37.19%	8/6/2025 (Estimated)

Latest LABU, MDGL, ARWR, and LABD Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
8/14/2025	Q3 2025	ARWR Arrowhead Pharmaceuticals	-$0.94	N/A	N/A	N/A	N/A	N/A
8/6/2025	Q2 2025	MDGL Madrigal Pharmaceuticals	-$3.64	N/A	N/A	N/A	$158.94 million	N/A
5/12/2025	Q2 2025	ARWR Arrowhead Pharmaceuticals	-$0.06	$2.75	+$2.81	$2.75	$116.27 million	$542.71 million
5/1/2025	Q1 2025	MDGL Madrigal Pharmaceuticals	-$3.62	-$3.32	+$0.30	-$3.32	$112.79 million	$137.25 million

Compare Dividends

Company	Annual Payout	Dividend Yield	3-Year Dividend Growth	Payout Ratio	Years of Consecutive Growth
ARWR Arrowhead Pharmaceuticals	N/A	N/A	N/A	N/A	N/A
LABD Direxion Daily S&P Biotech Bear 3x Shares	$0.27	4.14%	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	$0.32	0.51%	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ARWR Arrowhead Pharmaceuticals	0.31	5.15	5.15
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A	N/A	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A	N/A	N/A
MDGL Madrigal Pharmaceuticals	0.17	5.91	5.58

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ARWR Arrowhead Pharmaceuticals	62.61%
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A
MDGL Madrigal Pharmaceuticals	98.50%

Insider Ownership

Company	Insider Ownership
ARWR Arrowhead Pharmaceuticals	4.30%
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A
MDGL Madrigal Pharmaceuticals	21.50%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ARWR Arrowhead Pharmaceuticals	400	138.10 million	132.16 million	Optionable
LABD Direxion Daily S&P Biotech Bear 3x Shares	N/A	12.27 million	N/A	Not Optionable
LABU Direxion Daily S&P Biotech Bull 3x Shares	N/A	10.42 million	N/A	Not Optionable
MDGL Madrigal Pharmaceuticals	90	22.20 million	17.43 million	Optionable

LABU, MDGL, ARWR, and LABD Headlines

Recent News About These Companies

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffra™ (Resmetirom)

July 18 at 3:35 PM | taiwannews.com.twT

Madrigal Pharmaceuticals Hits 80-Plus Relative Strength Rating Benchmark

July 18 at 3:35 PM | msn.com

New York State Common Retirement Fund Boosts Holdings in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

July 18 at 4:17 AM | marketbeat.com

MDGL Stock Soars 11% on New Patent Protecting Rezdiffra Dosing Rights

July 17 at 12:35 PM | zacks.com

Madrigal (MDGL) Moves 10.9% Higher: Will This Strength Last?

July 17 at 8:11 AM | zacks.com

Madrigal stock jumps as patent protection for MASH treatment extended

July 16 at 8:21 PM | in.investing.com

Madrigal Pharmaceuticals shares surge after extended patent protection for MASH therapy

July 16 at 8:21 PM | msn.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Shares Gap Up - Should You Buy?

July 16 at 10:59 AM | marketbeat.com

Madrigal Pharmaceuticals Receives Notice of Allowance from U.S. Patent and Trademark Office for New U.S. Patent Covering Rezdiffraâ„¢ (Resmetirom)

July 16 at 8:13 AM | globenewswire.com

Emerald Advisers LLC Has $15.87 Million Stake in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

July 13, 2025 | marketbeat.com

Emerald Mutual Fund Advisers Trust Purchases 16,582 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

July 12, 2025 | marketbeat.com

D.A. Davidson & CO. Acquires 1,458 Shares of Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

July 10, 2025 | marketbeat.com

Cannon Global Investment Management LLC Makes New $497,000 Investment in Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL)

July 3, 2025 | marketbeat.com

Madrigal Pharma (MDGL) Share News Today - Investing.com UK

July 2, 2025 | uk.investing.com

JMP Reaffirms Price Target for Madrigal Amid Rezdiffra Growth Potential

July 2, 2025 | msn.com

Madrigal Pharmaceuticals, Inc. (NASDAQ:MDGL) Receives Consensus Rating of "Moderate Buy" from Analysts

July 1, 2025 | marketbeat.com

Madrigal, Viking among notable gainers after Altimmune’s MASH setback

June 26, 2025 | msn.com

Madrigal Pharmaceuticals Closer to EU Approval for First MASH Treatment, Rezdiffra

June 24, 2025 | msn.com

Madrigal Pharmaceuticals: GLP-1s Inch Closer To MASH Market As REZDIFFRA Outperforms

June 23, 2025 | seekingalpha.com

Madrigal Pharmaceuticals (NASDAQ:MDGL) Stock, Insider Trading Activity

June 21, 2025 | benzinga.com

EU regulator backs conditional authorisation for Madrigal's liver disease drug

June 20, 2025 | msn.com

New MarketBeat Followers Over Time

Media Sentiment Over Time

LABU, MDGL, ARWR, and LABD Company Descriptions

Arrowhead Pharmaceuticals NASDAQ:ARWR

$16.76 -2.09 (-11.09%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$16.86 +0.10 (+0.60%)

As of 07/18/2025 07:54 PM Eastern

Arrowhead Pharmaceuticals, Inc. develops medicines for the treatment of intractable diseases in the United States. The company's products in pipeline includes Plozasiran, which is in Phase 2b and one Phase 3 clinical trial to treat hypertriglyceridemia, mixed dyslipidemia, and chylomicronemia syndrome; Zodasiran that is in Phase 2b clinical trial for the treatment of dyslipidemia and hypertriglyceridemia; ARO-PNPLA3, which is in Phase 1 clinical trial to treat patients with non-alcoholic steatohepatitis; ARO-RAGE that is in Phase 1/2a clinical trial to treat inflammatory pulmonary conditions; and ARO-MUC5AC, which is in Phase 1/2a clinical trial to treat muco-obstructive pulmonary diseases. It also develops ARO-MMP7 that is in Phase 1/2a clinical trial for treatment of idiopathic pulmonary fibrosis; ARO-DUX4 for the treatment of facioscapulohumeral muscular dystrophy; ARO-SOD1 for the potential treatment of amyotrophic lateral sclerosis; and ARO-C3, which is in Phase 1/2a clinical trial for the treatment of patients with various complement mediated or complement associated renal diseases. In addition, the company is involved in the development of JNJ-3989, which is in Phase 2 clinical trial to treat chronic hepatitis B virus infection; Olpasiran that is in Phase 3 clinical trial to reduce the production of apolipoprotein A; GSK-4532990 that is in phase 2 clinical trial to treat liver diseases; HZN-457, which is in phase 1 clinical trial to treat uncontrolled gout; and Fazirsiran that is in Phase 3 clinical trial for the treatment for liver disease associated with alpha-1 antitrypsin deficiency. Arrowhead Pharmaceuticals, Inc. has license and research collaboration agreements with Janssen Pharmaceuticals, Inc.; Takeda Pharmaceutical Company Limited; Horizon Therapeutics Ireland DAC; Amgen Inc.; and Glaxosmithkline Intellectual Property (No. 3) Limited. The company was founded in 2003 and is headquartered in Pasadena, California.

Direxion Daily S&P Biotech Bear 3x Shares NYSEARCA:LABD

$6.52 +0.38 (+6.19%)

Closing price 07/18/2025 04:10 PM Eastern

Extended Trading

$6.50 -0.02 (-0.31%)

As of 07/18/2025 07:59 PM Eastern

The Direxion Daily S&P Biotech Bear 3X Shares (LABD) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times inverse exposure to the S&P Biotechnology Select Industry Index. LABD was launched on May 28, 2015 and is managed by Direxion.

Direxion Daily S&P Biotech Bull 3x Shares NYSEARCA:LABU

$62.76 -4.38 (-6.52%)

Closing price 07/18/2025 04:10 PM Eastern

Extended Trading

$63.13 +0.37 (+0.59%)

As of 07/18/2025 08:00 PM Eastern

The Direxion Daily S&P Biotech Bull 3X Shares (LABU) is an exchange-traded fund that is based on the S&P Biotechnology Select Industry index. The fund provides daily 3 times exposure to the S&P Biotechnology Select Industry Index. LABU was launched on May 28, 2015 and is managed by Direxion.

Madrigal Pharmaceuticals NASDAQ:MDGL

$334.13 -14.60 (-4.19%)

Closing price 07/18/2025 04:00 PM Eastern

Extended Trading

$332.00 -2.13 (-0.64%)

As of 07/18/2025 05:38 PM Eastern

Madrigal Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the development of therapeutics for the treatment of non-alcoholic steatohepatitis (NASH) in the United States. Its lead product candidate is resmetirom, a liver-directed thyroid hormone receptor beta agonist, which is in Phase 3 clinical trials for treating NASH. The company is headquartered in West Conshohocken, Pennsylvania.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Get 30 Days of MarketBeat All Access for Free

Start Your 30-Day Trial

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time